PharmTech Drug Digest 11.20
|Articles|October 15, 2008

SPL Now "Only Acceptable" Format for CBER Original Submissions

According to a July 11, 2008 memorandum posted by the Center for Biologics Evaluation and Research, starting Oct. 15, Health Level 7 structured product labeling in XML (extensible markup language) will be the only acceptable presentation in electronic format for the submission of content of labeling that CBER can process, review, and archive.

Rockville, MD (Oct. 15)-According to a July 11, 2008 memorandum posted by FDA's Center for Biologics Evaluation and Research (Docket FDA-1992-S-0039), starting Oct. 15, Health Level 7 (HL7) structured product labeling (SPL) in XML (extensible markup language) will be the only acceptable presentation in electronic format for the submission of content of labeling that CBER can process, review, and archive. The deadline applies only to the content of labeling with original submissions, supplements, and annual reports.

The agency encourages applicants to submit content according the July 2008, FDA Draft Guidance Providing Regulatory Submissions in Electronic Format-Drug Establishment Registration and Drug Listing, available here.

Moreover, FDA will hold a public workshop on Nov. 17 in Rockville, Maryland, to provide the biologics industry guidance on submitting content of labeling in SPL format. FDA will also present an overview of the agency’s voluntary pilot program for electronic submission of drug establishment registration and drug listing information.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.